Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall st set to open higher as chip stocks gain; US-Iran tensions in focus
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Xeris Pharmaceuticals Inc. (XERS) Tops Q2 EPS by 3c
August 10, 2022 7:06 AM EDTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $26.1 million.
GUIDANCE:
Xeris Pharmaceuticals Inc. sees FY2022 revenue of $105-120 million.
For... More
